NYSEAMERICAN:PLX - Protalix Biotherapeutics Stock Price, Price Target & More

Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX."

Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) posted its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.03. The firm had revenue of $4.55 million for the quarter, compared to the consensus estimate of $4.40 million. During the same quarter in the previous year, the business earned ($0.48) EPS. View Protalix Biotherapeutics' Earnings History.

1 equities research analysts have issued 12-month target prices for Protalix Biotherapeutics' stock. Their forecasts range from $5.00 to $5.00. On average, they anticipate Protalix Biotherapeutics' share price to reach $5.00 in the next year. View Analyst Ratings for Protalix Biotherapeutics.

Protalix Biotherapeutics saw a drop in short interest in the month of May. As of May 31st, there was short interest totalling 5,081,891 shares, a drop of 3.1% from the May 15th total of 5,242,949 shares. Based on an average daily volume of 416,075 shares, the short-interest ratio is currently 12.2 days. Approximately 3.7% of the company's stock are short sold.

Some companies that are related to Protalix Biotherapeutics include Biotest (BIO), ProMetic Life Sciences (PLI), Genfit (GNFTF), Mesoblast (MSB), Theratechnologies (TH), Mesoblast (MEOBF), Emerald Health Therapeutics (EMH), Starpharma (SPL), MediGene (MDG1), Oxford BioMedica (OXB), BioTime (BTX), Resverlogix (RVX), 22nd Century Group (XXII), Neptune Technologies & Bioressources (NEPT) and Monash IVF Group (MVF).

News headlines about PLX stock have trended somewhat positive this week, according to Accern. The research group scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Protalix Biotherapeutics earned a news sentiment score of 0.21 on Accern's scale. They also assigned news articles about the company an impact score of 45.23 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Protalix Biotherapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Opaleye Management Inc. (2.24%) and SG Americas Securities LLC (0.15%). Company insiders that own Protalix Biotherapeutics stock include Camber Capital Management Llc, Madalena Energy Inc, Moshe Manor, Randall Peel Boyd, Steve Dabner and Terence Stanley Meek. View Institutional Ownership Trends for Protalix Biotherapeutics.

PLX stock was bought by a variety of institutional investors in the last quarter, including Opaleye Management Inc. and SG Americas Securities LLC. Company insiders that have bought Protalix Biotherapeutics stock in the last two years include Moshe Manor, Randall Peel Boyd, Steve Dabner and Terence Stanley Meek. View Insider Buying and Selling for Protalix Biotherapeutics.

Shares of PLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PLX stock can currently be purchased for approximately $0.45.

Protalix Biotherapeutics has a market capitalization of $308.37 million.

Protalix Biotherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company can be reached via phone at +972-4-9028100.